Traditional clinical and pathological indicators, such as tumor size, grade, and lymph node involvement, along with the evaluation of specific biomarkers like estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), have historically played crucial roles in the staging and prognosis of breast cancer (Rakha et al. This evidence concerns the gene PGR and breast carcinoma.